- RecruitingPHASE3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
This study looks at a new drug, acoramidis, for people who have a faulty gene that can cause a condition called ATTR. It aims to see if the drug can stop or slow down the disease from developing in people who don't yet have symptoms.
For: Amyloidosis · Amyloid Cardiomyopathy · Transthyretin AmyloidosisUnited States · Argentina · Australia - RecruitingPHASE4
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
This study looks at changing from one heart medicine, tafamidis, to another, acoramidis, for a condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers want to see if switching to acoramidis increases levels of a special protein in your blood even more.
For: Transthyretin Amyloid CardiomyopathyAustria · Belgium · Germany